drugset / Trial / NCT07141706
A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a multicenter, open-label, multiple-dose, FIH Phase 1a/1b study. Phase 1a adopts an accelerated titration design and a BOIN design to identify the MTD or MAD of DB-1317; Phase 1b includes up to 3 randomized dose expansion cohorts to further evaluate the safety, tolerability and preliminary efficacy of DB-1317 in selected solid tumors and to identify optimal RP2D.
Timeline
- Start
- 2025-09-23
- Primary completion
- 2028-06
- Completion
- 2028-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DB-1317 | Unknown | — | Intravenous |
Indications
No indication recorded.